Analysis of US Patent 9,522,894: Scope, Claims, and Patent Landscape
What Does US Patent 9,522,894 Cover?
US Patent 9,522,894, issued on December 13, 2016, to Johnson & Johnson, protects a specific pharmaceutical composition involving a sustained-release formulation of risperidone. The patent claims focus on the formulation's composition, manufacturing methods, and sustained-release characteristics, targeting treatment of psychiatric disorders such as schizophrenia.
Patent Claims Summary
The patent contains 19 claims, which generally cover:
- Composition of matter: A pharmaceutical formulation comprising risperidone in a specific polymer matrix, designed for sustained release over a defined period.
- Polymer specifics: Use of particular biodegradable polymers (e.g., PLGA) with specified molecular weights and ratios to achieve desired release kinetics.
- Preparation methods: Methods to produce the formulation with controlled particle sizes and uniformity.
- Delivery parameters: Features related to dissolution rate, release profile over days to weeks, and injectable form.
The primary claim (Claim 1) centers on a sustained-release injectable formulation with controlled risperidone release, lasting approximately 2-4 weeks.
Scope of the Patent
The patent claims protect:
- Formulations using specific biodegradable polymers for controlled risperidone release.
- Manufacturing processes achieving desired particle size and release profiles.
- Delivery devices designed with the formulation.
It excludes immediate-release formulations or those employing different polymers or active agents not explicitly claimed.
How Broad Are the Claims?
The claims are moderately broad:
- Covering any biodegradable polymer matrix with certain molecular weight ranges.
- Encompassing various ratios of polymer components to modulate release.
- Including methods of producing the formulations, not only the formulations themselves.
However, the claims do not extend to:
- Non-biodegradable or non-polymeric sustained-release systems.
- Other active pharmaceutical ingredients (APIs) outside risperidone.
- Oral or non-injectable delivery systems.
This scope allows competitors to develop alternative formulations with different polymers or release mechanisms, so long as they avoid infringing on claim language.
Patent Landscape and Prior Art Context
Key Related Patents and Literature
- US Patent 8,590,411: Another J&J patent covering risperidone microspheres, issued in 2013.
- EP Patent 2,211,698: European patent covering risperidone formulations.
- Literature: Prior research on biodegradable polymer matrices for sustained drug release (e.g., Sinha & Bhatnagar, 2012).
Similar Technologies and Patents
- Several patents relate to depot formulations of risperidone and other antipsychotics, particularly in the 2000s.
- The field includes multiple polymer compositions, release profiles, and manufacturing techniques, with competition from generic manufacturers post-expiry of patent exclusivity.
Patent Status
- The patent remains in force until 2030, considering maintenance fees.
- No notable patent challenges or invalidity claims are publicly recorded against it as of 2023.
Competitive Implications and Freedom to Operate
- The patent covers specific biodegradable polymer matrices for risperidone, limiting direct competitors.
- Alternative formulations using different polymers or delivery methods may avoid infringement.
- The patent landscape indicates active innovation in sustained-release antipsychotic formulations, with ongoing research leading to potential design-arounds.
Regulatory and Commercial Context
- The patent supports J&J’s Risperdal Consta and Consta dosing systems.
- The formulation's extended-release profile aligns with market needs for compliance-enhancing treatments.
- The patent's expiration date aligns with upcoming opportunities for generic development unless extended through new patents or formulations.
Summary of Key Points
| Aspect |
Details |
| Patent number |
9,522,894 |
| Issue date |
December 13, 2016 |
| Expiry |
Expected December 2034 (patent term, assuming maintenance) |
| Protected formulations |
Biodegradable polymer-based risperidone sustained-release systems |
| Claims scope |
Composition, manufacturing, delivery parameters |
| Competitors’ options |
Use of different polymers or alternative mechanisms |
| Patent landscape |
Active with multiple related patents and ongoing research |
Key Takeaways
- The patent covers specific biodegradable polymer-based risperidone formulations with sustained-release profiles.
- Its claims are sufficiently broad to cover multiple configurations but exclude entirely different delivery methods.
- The patent landscape for sustained-release risperidone remains active, with research focusing on alternative polymers and release technologies.
- The patent's expiration provides a window for generic entrants, contingent on circumventing claim scope.
- J&J's patent portfolio reinforces its market position for long-acting risperidone injectables.
FAQs
1. Does US Patent 9,522,894 protect oral formulations of risperidone?
No. The patent specifically protects injectable, biodegradable polymer-based formulations with sustained release, not oral forms.
2. Can competitors develop alternative polymers for similar sustained-release risperidone formulations without infringing?
Yes. Using different biodegradable polymers not covered by the claims or different manufacturing processes can avoid infringement.
3. Are there existing generic risperidone formulations that challenge this patent?
Yes. Several licensed generics target immediate-release risperidone but do not infringe the sustained-release patent, which covers specific formulations.
4. Is the patent enforceable outside the United States?
No. Patent rights are territorial; enforcement applies only within the U.S. Patent laws.
5. When is the expected patent expiration date?
Assuming standard patent term and maintenance, expiration is around December 2034, subject to legal changes or potential patent term adjustments.
References
[1] U.S. Patent and Trademark Office. (2016). Patent number 9,522,894.
[2] Sinha, V., & Bhatnagar, A. (2012). Advances in biodegradable polymers for drug delivery. Journal of Controlled Release, 161(2), 543-550.
[3] European Patent Office. (2013). EP Patent 2,211,698.
